It was lovely to speak with Dr Beatriz Mateos (Universidad de Alcalá, Madrid, Spain) about the findings from her research into the impact of tenofovir on the severity of COVID-19 infection in those with chronic hepatitis B.
Her presentation entitled ‘Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients’ was given at EASL ILC 2021, 23-26 June.
Questions
- What was the rationale for investigating antiviral treatments, such as tenofovir and entecavir, in the treatment of COVID-19 infection for those with chronic hepatitis B? (0:23)
- Could you briefly summarise the aims of your study, the methods used and the analysis performed? (1:00)
- What were the key clinical findings from the research? (2:23)
- Based on these findings, could tenofovir be providing a protective effect from severe COVID-19 symptoms and what could the clinical impact of these findings be? (3:09)
Disclosures: Dr Beatriz Mateos has nothing to disclose in relation to this video interview
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
